1-(3-氯苯基)-2-酮哌嗪 | 183500-70-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(3-氯苯基)-2-酮哌嗪
• 中文别名: 1-(3-氯苯基)-2-哌嗪酮
• 英文名称: 1-(3-chlorophenyl)-2-piperazinone
• 英文别名: 1-(3-Chlorophenyl)piperazin-2-one
• CAS: 183500-70-1
• 化学式: C₁₀H₁₁ClN₂O
• 分子量: 210.663
• InChiKey: SQLHSSGGJDQOTB-UHFFFAOYSA-N

物化性质

• 沸点：
  443.9±40.0 °C(Predicted)
• 密度：
  1.267±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-(3-氯苯基)-2-酮哌嗪 在 甲醇 、 四(三苯基膦)钯 、 三乙酰氧基硼氢化钠 、 potassium carbonate 作用下， 以 乙二醇二甲醚 、 氯仿 、 水 、 1,2-二氯乙烷 为溶剂， 生成 1-(3-Chloro-phenyl)-4-{3-[6-(4-trifluoromethyl-phenyl)-pyridin-3-ylmethyl]-3H-imidazol-4-ylmethyl}-piperazin-2-one
  参考文献：
  名称：

  Potent inhibitors of farnesyltransferase and geranylgeranyltransferase-I

  摘要：

  Compound 1 has been shown to be a dual prenylation inhibitor with FPTase (IC50 = 2 nM) and GGPTase-1 (IC50 = 95 nM). Analogues of 1, which replaced the cyanophenyl group with various biaryls, led to the discovery of highly potent dual FPTase/GGPTase-1 inhibitors. 4-Trifluoromethylphenyl, trifluoropentynyl, and trifluoropentyl were identified as good p-cyano replacements. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(02)00154-3
• 作为产物：
  描述：

  间氯溴苯 在 盐酸 、 palladium diacetate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 生成 1-(3-氯苯基)-2-酮哌嗪
  参考文献：
  名称：

  QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF

  摘要：

  化合物的分子式是(I)，是一种四元内酰胺化合物。该化合物用于制造治疗和/或预防血栓性或栓塞性疾病的药物。

  公开号：

  US20210032219A1

文献信息

• Method of treating cancer
  申请人：——

  公开号：US20030220241A1

  公开（公告）日：2003-11-27

  The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

  本发明涉及使用一种PSA共轭物和一种前脂蛋白转移酶抑制剂的组合治疗癌症的方法，该方法包括向所述哺乳动物施用来自以下组中选择的至少两种治疗剂的量，所述组包括一种PSA共轭物和一种前脂蛋白转移酶抑制剂，所述治疗剂可以顺序给药或同时给药。该发明还涉及制备这种组合物的方法。
• Receptor Antagonists
  申请人：——

  公开号：US20040110826A1

  公开（公告）日：2004-06-10

  The present invention provides an &agr; 2c -adrenoceptor antagonist comprising, as an active ingredient, a condensed-ring-pyrimidine derivative represented by general formula (I) below or a pharmaceutically acceptable salt thereof useful for treating and/or preventing various diseases induced by hyperactivity of &agr; 2c -adrenoceptor (for example, Parkinson's disease, L-DOPA-induced dyskinesia, tardive dyskinesia and depression) and the like. 1 {wherein p represents an integer of 1 to 3; R 1 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —N(—R 4 )(—R 5 ) (wherein R 4 and R 5 are the same or different, and each represents a hydrogen atom, substituted or unsubstituted aralkyl, or the like, or R 4 and R 5 form a substituted or unsubstituted heterocyclic group together with the adjacent nitrogen atom) or the like; and -Q- represents —N═C(—R 7 )— [wherein R 7 represents —N(—R 9 )(—R 10 ) (wherein R 9 and R 10 are the same or different, and each represents substituted or unsubstituted aralkyl, or the like, or R 9 and R 10 form a substituted or unsubstituted heterocyclic group together with the adjacent nitrogen atom) or the like] or the like}

  本发明提供一种α2c-肾上腺素受体拮抗剂，其包括以下通式（I）所代表的紧缩环嘧啶衍生物或其药学上可接受的盐作为活性成分，用于治疗和/或预防由α2c-肾上腺素受体过度活跃引起的各种疾病（例如帕金森病、L-多巴诱导的运动障碍、迟发性运动障碍和抑郁症）等。 其中，p表示1到3的整数； R1代表取代或未取代的杂环基团、取代或未取代的芳基等； R2代表—N(—R4)(—R5)（其中R4和R5相同或不同，每个代表氢原子、取代或未取代的芳基烷基等，或R4和R5与相邻氮原子一起形成取代或未取代的杂环基团）等；以及 -Q-代表—NHC(—R7)— [其中R7代表—N(—R9)(—R10)（其中R9和R10相同或不同，每个代表取代或未取代的芳基烷基等，或R9和R10与相邻氮原子一起形成取代或未取代的杂环基团）等]等。
• Inhibitors of farnesyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US05856326A1

  公开（公告）日：1999-01-05

  The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

  本发明涉及抑制法尼基-蛋白转移酶（FTase）和致癌基因蛋白Ras法尼酰化的化合物。该发明还涉及含有本发明化合物的化疗组合物以及抑制法尼基-蛋白转移酶和致癌基因蛋白Ras法尼酰化的方法。
• [EN] 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS<br/>[FR] DÉRIVÉS DE 4-BENZOYL-1-SUBSTITUÉ-PIPÉRAZIN-2-ONE COMME MODULATEURS DE P2X7
  申请人：GLAXO GROUP LTD

  公开号：WO2009053459A1

  公开（公告）日：2009-04-30

  The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein: A is C1-6alkyl, C3-6cycloalkyl, -CH2-R6, -CHMe-R7, -CMe2-R7, or optionally substituted aryl; wherein, when A is optionally substituted aryl, said aryl group is optionally substituted with 1 to 3 substituents, which may be the same or different, selected from the group consisting of halogen, C1-6alkyl, -CF3, C1-4alkoxy, C1fluoroalkoxy, cyano, NR8R9; and pyridyl wherein the pyridyl is optionally substituted by one methyl; R1 is chlorine, fluorine, -CF3, cyano or C1-6alkyl; R2, R3 and R5 independently are hydrogen, fluorine, chlorine, -CF3, cyano or C1-6alkyl, such that at least one of R2, R3 and R5 is other than hydrogen; R4 is hydrogen. These compounds and salts are thought to be P2X7 receptor antagonists. The invention also provides the use of the compound or salt for the manufacture of a medicament for the treatment of pain, inflammation, rheumatoid arthritis, osteoarthritis, or a neurodegenerative disease.

  该发明提供了一个具有以下式（I）的化合物或其药用盐，其中：A为C1-6烷基，C3-6环烷基，-CH2-R6，-CHMe-R7，-CMe2-R7或可选择地取代的芳基；其中，当A为可选择地取代的芳基时，所述芳基可选择地取代为1至3个取代基，这些取代基可以相同或不同，选自卤素，C1-6烷基，-CF3，C1-4烷氧基，C1氟烷氧基，氰基，NR8R9；和吡啶基，其中吡啶基可选择地被一个甲基取代；R1为氯，氟，-CF3，氰基或C1-6烷基；R2、R3和R5独立地为氢，氟，氯，-CF3，氰基或C1-6烷基，使得R2、R3和R5中至少有一个不是氢；R4为氢。这些化合物和盐被认为是P2X7受体拮抗剂。该发明还提供了该化合物或盐用于制备用于治疗疼痛、炎症、类风湿关节炎、骨关节炎或神经退行性疾病的药物的用途。
• Inhibitors of prenyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US06387903B1

  公开（公告）日：2002-05-14

  The present invention is directed to compounds which inhibit prenyl-protein transferases, farnesyl-protein transferase and geranylgeranyl-protein transferase type I, and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and geranylgeranyl-protein transferase type I and the prenylation of the oncogene protein RAS.

  本发明涉及抑制戊二烯基蛋白转移酶、法尼基蛋白转移酶和戊二烯基蛋白转移酶I型，以及癌基因蛋白Ras的预醇化的化合物。本发明还涉及含有本发明化合物的化疗组合物，以及抑制法尼基蛋白转移酶和戊二烯基蛋白转移酶I型以及癌基因蛋白Ras的预醇化的方法。